Introduction
A number of neurodevelopmental disorders with intellectual disability harbour chromosomal microdeletions or microduplications. Deletions or duplications larger than 5 Mb can be usually detected by the cytogenetic analysis of banded karyotypes. However, microdeletions are deletions of a smaller scale, typically 1-3 Mb, and cannot be detected by conventional cytogenetic tests conducted with light microscopy. These deletions and duplications can be discovered by array-based comparative genomic hybridisation 1 , fluorescent in situ hybridisation or quantitative real-time polymerase chain reaction, if applicable 2 . The variable sizes and locations of microdeletions or microduplications have been identified in such syndromes, however, a specific 'critical region' for each respective disorder has been consistently observed. Furthermore, the whole-genome sequencing technology facilitates detection of new mutations and has been useful in re-examining cohorts of patients with the relevant genetic diseases. Such developments in genetic detection techniques have led to discoveries in the molecular pathways that are critical in the pathophysiology of these disorders. Most phenotypic effects of these syndromes are due to haploinsufficiency (microdeletion) or overexpression (microduplication) of either a few critical genes, or in some cases, a single gene. Monogenic disorders are diseases in which a single pair of genes is responsible for the emergence or absence of a particular group of symptoms or phenotypes. Such monogenic neurodevelopmental disorders may aid in the understanding of molecular and cellular aspects of gene-brainphysiology and may provide insight into the neurobehavioural impacts of genetic variation. They may also aid in the exploration of effective treatments for such syndromes by deciphering networks between the different neurophysiological phenotypes originating from the single causal gene. Studying the precise causal mechanisms of monogenic neurodevelopmental disorders will not only lead to a better understanding of these syndromes and the development of potential treatments but also provide insights into the broader autism spectrum disorders (ASD) and related disorders. In this article, several highly penetrant monogenic disorders that show early onset are introduced as possible candidates to study neurodevelop-mental disorders. Disorders that are characterised with late onset are expected to have complications arising from the patients' environment and the patients' history of treatments, which may be the causes for the increased variation observed between the samples.
Discussion
G enetic disorders of intellectual disability related with ASD Smith-Magenis syndrome (SMS) (OMIM#182290) is a complex neurobehavioural disorder with a prevalence of approximately 1:20,000 live births 3 . It is characterised by intellectual disabilities and sleep disturbances associated with developmental anomalies including craniofacial and skeletal disorders 4, 5 . All of the SMS cases carry either a microdeletion at chromosome 17p11.2 or a mutation in the retinoic acid-induced 1 (RAI1) gene at chromosome 17p11.2 region 4, 6 . RAI1 is a transcription factor comprising of six exons, with most of the coding sequence located in the third exon where the majority of the SMS associated de novo mutations can be found, suggesting that a functional RAI1 gene dosage is responsible for the SMS phenotype 7 . On the contrary, overexpression of RAI1, i.e. duplication of 17p11.2 causes the Potocki-Lupski syndrome (PTLS, OMIM#610883) 8 . Like SMS, the PTLS is a neurodevelopmental disorder characterised by hypotonia, failure to thrive, mental retardation, pervasive developmental disorders and congenital anomalies. The RAI1 protein includes a bibartite nuclear localisation signal and zinc fingerlike plant homeo domain, which has been found in many chromatinassociated proteins. RAI1 is one of the candidate genes for susceptibility of ASD 5, 8 . Little is known about the genes regulated by RAI1 in the central nervous system; a recent study shows that RAI1 regulates the transcription of the circadian locomotor output cycles kaput (CLOCK) gene that transcriptionally regulates many critical circadian genes 9 , as well as the BDNF gene 10 , previously implicated in autism 11 14 . Recessive forms of PTHS are caused by mutations in the Neurexin 1 (NRXN1) and contactin-associated protein-like 2 (CNTNAP2) genes. The NRXN1 and CNTNAP2 proteins are members of the neurexin family, and they function in the nervous system as cell adhesion molecules and receptors and contribute in synaptic scaffolding 15 . Again, NRXN1 deletions have been reported in schizophrenia 16 , and CNTNAP2 is one of the ASD susceptibility genes 17 . The 2q23.1 microdeletion syndrome, also known as autosomaldominant mental retardation type 1 (MRD1, OMIM# 156200) is caused by haploinsufficiency of the methylCpG-binding domain 5 (MBD5, OMIM#611472) at 2q23.1 18, 19 . The phenotypic feature of MRD1 includes intellectual disability, severe speech impairment, seizures, behavioural problems and microcephaly. The MBD5 is a member of the methyl CpG-binding domain protein family, which also comprises MECP2, encoded by the X-linked gene that is mutated in the autistic neurodevelopmental disorder Rett's syndrome (RTT, OMIM#312750). RTT patients are considered as a part of the ASD population and the syndrome is characterised by arrested development, regression of acquired skills, impaired motor function, microcephaly, seizures and mental retardation 20 . Investigation into the epigenetic mechanisms involved in the aetiology of the above disorders may provide crucial insights into the mechanisms of interaction of autism susceptibility genes with environmental exposures and/or genes responsive to environmental insult. Such epidemiological research on the interaction between genetic/epigenetic and brain mechanisms underlying the development, control and modulation of behaviours, will provide new and important knowledge regarding these complex brain disorders and aid in the improvement of their treatments.
'Disease-in-a-dish' approach to neurodevelopmental disorders
Obvious limitations exist in accessing neuronal tissues in human studies of neurodevelopmental disorders. Transgenic mouse models exist for SMS and PTLS but not for PTHS 21 and MRD1. Moreover, it is a challenge to define the degree to which the mouse model recapitulates the human phenotype 22, 23 . Some degree of dosage effects of the SMS can be manifested in the mouse models 24, 25 , however, it is difficult to assess the complex phenotypes of human studies and compare the phenotypes at the cellular levels. The cerebral cortex conducts important cognitive and executive roles in the mammalian central nervous system. The cortical neurons are believed to be relevant cell types for the study of many psychiatric disorders. The primate cerebral cortex, especially the human cerebral cortex, has major differences from that of the rodents, in terms of its size, complexity and the nature of the stem cell populations 26 . Cell divisions are observed in a significantly larger germinal region of the foetal cortex in primates but not in rodents all classes of human cortical projection neurons carrying various genetic backgrounds linked to the diseases could be obtained, it would present a promising potential to address the challenges faced in mouse models while replicating the pathogenesis of cortical defects (see sub-section on 'Differentiation of iPSC into neuronal cells in vitro', below).
Takahashi 28 . Since 2007, there have been numerous reports on the generation of iPSCs from human somatic cells 29, 30 . Most of the iPSC generations of the ASD model were employed with retroviral or lentiviral transduction of reprogramming factors into somatic cells (Table 1) . Though this method is more efficient in generating iPSCs as compared with other approaches, there are some obvious drawbacks. These drawbacks are particularly observed in the lentiviral approach, which results in the random integration of transgenes into the genome resulting in insertional mutagenesis, continued expression of the transgenes interfering with the downstream differentiation processes and heterogeneity among the established cell lines. To facilitate consistent detection of phenotypic differences between iPSC lines established from the patients and controls, improved reprogramming technologies including an integration-free episomal plasmid-based approach and mRNA or protein transductions, have been recommended 31, 32 . Some studies have found that viral-mediated iPSCs produce less proliferative neural progenitor cells. It has been reasoned that the residual expression of an exogenous reprogramming gene integrated into the host genome, induced the p53 pathways 33 . Integration of reprogramming vectors into the host genome can lead to disruption or dysregulation of adjacent genes and may cause the residual expression of transgenes 34 . Even though the episomal plasmid-mediated approach is less efficient and results in a reduced number of iPSC colonies when compared to the lentiviral approach, the generated iPSC lines lack the integration sites of the reprogramming vectors and therefore show less variability among the lines. A protocol developed by Okita et al. 35 includes episomal vectors carrying novel elements such as shRNA for p53 suppression and nontransforming L-Myc, in addition to the usual combination of reprogramming genes such as POU5F1, SOX2, KLF4 and LIN-28. In this method, integration-free iPSCs can be generated in three weeks with a single transfection, and this is applicable for various types of primary cells including human skin fibroblasts. Phenotypic variability in iPSC lines generated from a single patient can obscure causal differences of the disease. To reduce such variability in iPSC lines, incompletely reprogrammed iPSCs (pre-iPSCs) have to be excluded from the iPSCs to be characterised. The pre-iPSCs are dependent on the expression of exogenous transgenes with insufficient expression of the endogenous pluripotent genes 36 . The pluripotency validations of human embryonic stem cells (ESC) and iPSCs (both termed as 'hPSC') have been included with the teratoma assay in immunodeficient mice, a method that harbours technical variations and relatively lacks clear standards. An alternative bioinformatics assay called Pluritest 37, 38 has been proposed to standardise and expedite the testing procedure for proving pluripotency, with the utilisation of microarray-based gene expression datasets. Table 1 . Reported iPSC genera on for cellular modeling of au sm spectrum disorders.
Diseases

Gene c muta on References
Re 's syndrome iPSCs established from the patients' skin fibroblasts provide a unique model for studying genetic disorders. As the iPSC proliferates for many doublings without showing any signs of senescence, the generated iPSCs can be an unlimited source of human neuronal cells carrying the genetic variation that causes the specific disorder. Their extended cellular life spans ensure that the resultant iPSC lines can be employed in multiple experiments. The iPSCs share characteristics of ESCs that can give rise to the three germ layers and recapitulate early stages of differentiation processes in vitro. Surprisingly, the genomic imprinting status of iPSCs derived from patients of imprinting disorders, such as the AS and PraderWilli syndrome (OMIM #176270), were not erased during reprogramming and the differentiated neurons were used as cellular models of the imprinting diseases 39, 40 . The prominent neurobehavioural phenotypes that feature on the SMS and RTT for example, start emerging between 18-36 months and 6-18 months of age, respectively, and the motor delays and maladaptive behaviours of SMS can be observed earlier than 18 months of age 5, 20 . Such manifestation timing of the neurobehavioural symptoms after neurogenesis suggests that the disorders include defects in synaptic maturation, cortical connectivity and stabilisation 15, 41 . To investigate the manifestation of aetiology at the crucial timing, access to cellular and molecular dynamics during the multiple neurodevelopmental stages will provide important insights into the mechanisms of these disorders. The 'disease-in-a-dish' 42 approach, employing the differentiating iPSCs from the patients' somatic cells to model the disease in vitro, is a unique avenue to access such cellular information. Patient derived iPSC models of diseases, with strong genetic basis and high penetrance, are expected to be most informative for drug screenings 43 . Many studies have shown the feasibility of using iPSCs as a cellular disease model of ASD (Table 1) .
Diff erentiation of iPSCs into neuronal cells in vitro
Efficient neural differentiation into cerebral cortex stem cells and progenitor cells facilitates the creation of ex vivo models of neural networks.
To produce neurons of a desired subtype, deriving the correct type of progenitor cell is essential. Cortical neurons consist of interneurons and projection neurons. The former are inhibitory, gamma-aminobutyric acid-ergic neurons and contribute to local connections, while the latter are pyramidal shaped, excitatory, glutamatergic neuron and extend their axons to distant regions of the other cortex and to other regions of the brain 44 . The inhibitory interneurons are generated in the ventral telencephalon (subpallium) and migrate into the dorsal telencephalon (pallium) while the excitatory projection neurons are generated in the cortical neuroepitherium.
Many human iPSC lines derived from these patients were differentiated into neural cells (Table 1) , however, the regional identity in the nervous system as well as the cell types in which pathogenesis typically occur, have not been fully addressed 45 . The assumption that limited characterisation of differentiated cell types would validate a cell type as it exists in vivo, has been criticised as 'a major pitfall' recently 46 . Improvement of the differentiation protocols and careful comparison of the cell types are required if the field is to advance. Eiraku et al. established a procedure, wherein the mouse ECSs differentiated into distinct cortical neurons, by employing the formation of cellular aggregates (also known as embryoid body) that followed an in vivo-mimicking developmental order and led to the selective generation of particular layer-specific neurons 47 . Recently, by following this method, generation of such late-developing neurons from human iPSC with expressions of a spectrum of forebrain layer-specific cortical neurons has been achieved 48, 49 . Employing a similar cell aggregation method, the hPSCs have been differentiated to produce the forebrain neurons 50, 51 . The differentiated cells expressed TBR1 or CTIP2, expressing glutamatergic neurons at the subcerebral layer. However, these papers did not characterise the derivation of laterdeveloped upper layer neurons 51 . An in vitro differentiation protocol for the generation of excitatory glutamatergic neurons from hPSCs, representing both the deeper and upper cortical layers, has also been reported 52, 53 . This protocol modified the preceding adherent culture conditions 54 by combining retinoid signals with the inhibition of SMAD signalling that improved the conversion efficiency of the cells into cortical progenitor cells. STEMCELL Technologies (Vancouver, Canada) provides a different system for efficient neural induction from hPSCs using a combination of a specialised multiwall-plate and a defined serumfree neural differentiation medium. The multiwall-plate has microwells of 800 μm in width that results in uniformity of size and shape during aggregate generation. The defined homogeneous aggregate size can improve reproducibility of differentiation experiments and influence the efficiency of neural differentiation 55, 56 . Such Incorporation of biomaterials and bioengineering techniques enhanced the conversion of hPSCs into neural progenitor cells. There are improved differentiation procedures that allows recapitulating series of developmental stages in human cortex neurons and generates extensive classes, including an upper layer of cortical neurons from hPSCs 45, 48, 52, 53, 57 .
Conclusion
In disorders. The generated patientspecific iPSCs can be reproducibly differentiated into the cell types in which the disease manifests. The iPSCs allow almost limitless access to the cellular materials and provide an unanticipated possibility for dissecting disease mechanisms and novel drug candidates for therapy. A number of limitations and challenges in this approach have to be addressed for it to be successful and reliable. Improved methodology and more sensitive analysis will be required to enable the detection of subtle yet consistent and important differences between controls and patients' cell lines. Improved technologies are being generated at an increased pace in the recent years. More studies in monogenic neurological disorders that show highly penetrant and early onset syndromes such as SMS, PTLS, PTHS and MRD1, will not only improve the overall understanding of these syndromes but also provide useful insight into the complex nature of these brain disorders, including ASD and related disorders. A significant milestone in this approach can be achieved if the monogenic disorder studies can be confirmed with gain-and loss-offunction studies in the future. 
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